“We expect to start seeing the Impact from this initiative towards the end of 2024.”

In context

“oss Europe and other geographies, such as in Japan where we have seen good progress in growing brand share and expanding our network of authorized treatment centers to over 20 to date. In the U.S., and consistent with our recent updates, we see opportunity for growth through expanding the number of authorized treatment centers and affiliated satellites, while also driving increased referrals from the community setting. For example, we're proud to have established our flagship community collaboration with Tennessee Oncology in the first quarter. We’'ve identified many critical learnings on how we can partner effectively with community oncology practices for cell therapy, and we will continue to refine this “blueprint” so that we become more efficient at onboarding new centers over time. We expect to start seeing the Impact from this initiative towards the end of 2024. Wrapping up the first quarter, we had a strong start to the year, primarily driven by higher demand across each of our core businesses year-over-year. We look forward to carrying this momentum through 2024 and as we bring seladelpar to market later this year following approval. I’d like to thank the commercial teams and cross-functional partners across Gilead and Kite for their strong execution as we diligently expand our therapies to new populations, positively impacting more people all around the world. And with that, I’'ll hand the call over to Merdad. Merdad Parsey: Thank you, Johanna. We have had a busy first quarter at Gilead, with a cadence of clinical readouts that will continue throughout the rest of the year. Importantly, we anticipate an FDA regulatory decision on selade”